Start here if you're new
what it is
Cibus edits seed traits so crops can fight weeds, disease, and other farm headaches with less chemical help.
how it gets paid
Last year Cibus made $4M in revenue. trait licensing and collaboration revenue was the main engine at $1.6M, or 40% of sales.
what just happened
Last quarter delivered $3M of revenue, but Cibus still lost $2.21 a share.
At a glance
C balance sheet — red flag territory — real financial stress
5/100 earnings predictability — expect surprises
-$3.02 fy2024 eps est
$4M fy2024 rev est
n/a operating margin
xvary composite: 19/100 — weak
What they do
Cibus edits seed traits so crops can fight weeds, disease, and other farm headaches with less chemical help.
Its edge is speed. Cibus says its RTDS platform powers a pipeline of 5 productivity traits, which matters when you only have 157 employees and need each program to count. Licensing plant traits instead of selling seeds means you want partners doing the heavy lifting while you keep the science.
How they make money
$4M
annual revenue
trait licensing and collaboration revenue
$1.6M
+320%
partner-funded ingredient projects
$1.0M
+320%
research and development services
$0.8M
74.3%
milestone and other revenue
$0.6M
74.3%
The products that matter
gene-editing trait platform
RTDS gene editing platform
core asset · $4M company revenue
it underpins the whole business, but the company still only generates $4M in annual revenue, so the platform's value remains mostly unproven in the market.
core platform
commercial trait licensing
rice & canola traits
jan 2025 milestone
management said production standards were established in january 2025. that matters because a company with $4M in revenue needs real partner adoption, not just lab progress.
commercial test
future launch pipeline
trait pipeline
nov 2025 update
a november 2025 report cited launch readiness. if that does not start converting into revenue after a +138.9% growth year, the story gets harder to fund.
execution watch
Key numbers
$4M
annual revenue
That is the whole business for 2024. Against a roughly $257 million market cap, you are paying about 64 times sales for a company still losing money.
n/a
operating margin
Prior margin KPI failed sanity check — verify in filings. Operating margin → profit after running the business → so what: Cibus loses about $60 for every $1 of revenue.
$256M
long-term debt
Debt → money that must be repaid → so what: debt is about equal to the entire market cap and 64 times annual revenue.
5/100
price stability
Price stability → how calm the stock trades → so what: this share price is built for drama, not sleep.
Financial health
C
strength
- balance sheet grade C — very weak — significant financial distress
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $256M (50% of capital)
C — balance sheet grade and long-term debt are flagged. this stock carries more risk than average.
Total return vs. market
Return history isn't available for CBUS right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Last quarter delivered $3M of revenue, but Cibus still lost $2.21 a share.
Revenue jumped 320% vs. prior year in the latest quarter, but the full-year picture is still tiny at about $4 million. The business remains deep in the red, with a 2024 EPS estimate of -$3.02 and operating margin n/a (verify filings).
$3M
revenue
$2.21
eps
n/a
operating margin
the number that mattered
$3 million of quarterly revenue matters because it is 75% of the entire annual revenue base, which shows how lumpy and fragile this business still is.
source: EDGAR filings and company earnings data, 2025
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is commercialization arriving too late for a leveraged balance sheet.
high
financial distress
$256M in long-term debt against $4M in annual revenue is the story. a C balance sheet means future financing terms matter almost as much as crop-trait adoption.
quantified impact: the debt load equals roughly the entire ~$257M market cap.
high
commercial adoption stays slow
the company grew revenue +138.9%, but the base is still just $4M. if seed partners do not move from evaluation to licensing, the income statement stays tiny while the balance sheet does not.
quantified impact: 100% of current revenue is only $4M.
med
execution risk between milestones and money
january 2025 production standards and november 2025 launch-readiness language are useful milestones. they are not the same thing as recurring commercial revenue.
watch the gap between operational updates and actual reported sales.
med
stock volatility
a 1.7 beta and 5 / 100 price stability tell you this stock can swing hard even before the underlying business changes much. that volatility cuts both ways, but mostly tests your timing.
quantified impact: the shares traded between $1 and $4 over the last 52 weeks.
$256M of debt, $4M of revenue, and a C balance sheet mean the financing clock matters almost as much as the technology.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
march 17, 2026 earnings report
this is the next hard checkpoint. after a Q3 2025 miss, you want to see whether revenue starts catching up to the commercialization narrative.
metric
revenue above the $4M level
the company can tell a better story than the numbers today. until annual revenue moves materially beyond $4M, the market is still paying mostly for optionality.
balance sheet
debt and any financing updates
$256M in long-term debt is heavy for this scale. any refinancing, restructuring, or capital raise would tell you how much time management really has.
commercial trend
trait launches turning into partner revenue
january 2025 standards and november 2025 launch-readiness are milestone language. the trend that matters next is signed partners and reported dollars.
Analyst rankings
earnings predictability
5 / 100
earnings are hard to model here. in human-speak, analysts do not trust quarter-to-quarter consistency.
risk rank
5
safer than 5% of stocks. plain english: riskier than almost everything else you could buy.
price stability
5 / 100
this is not a steady compounder. the share price tends to behave like a high-volatility development story.
source: institutional data
Institutional activity
institutional ownership data for CBUS is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$2
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive